View in EDS

Phase II Study of the Dual EGFR/HER3 Inhibitor Duligotuzumab (MEHD7945A) versus Cetuximab in Combination with FOLFIRI in Second-Line RAS Wild-Type Metastatic Colorectal Cancer.

Saved in:
Bibliographic Details
Title: Phase II Study of the Dual EGFR/HER3 Inhibitor Duligotuzumab (MEHD7945A) versus Cetuximab in Combination with FOLFIRI in Second-Line RAS Wild-Type Metastatic Colorectal Cancer.
Authors: Hill AG; Tasman Oncology Research, Southport, Australia. andrewgrahamhill@gmail.com., Findlay MP; Discipline of Oncology, University of Auckland, Auckland, New Zealand., Burge ME; Royal Brisbane and Women's Hospital, Herston, Australia; University of Queensland, Queensland, Australia., Jackson C; Department of Medicine, Dunedin School of Medicine, University of Otago, Dunedin, New Zealand., Alfonso PG; Gregorio Marañón Hospital, Madrid, Spain., Samuel L; Aberdeen Royal Infirmary, Aberdeen, United Kingdom., Ganju V; Peninsula Oncology Centre, Frankston, Australia., Karthaus M; Staedtisches Klinikum Muenchen GmbH-Klinikum Neuperlach, Munich, Germany., Amatu A; Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milan, Italy., Jeffery M; Canterbury Regional Cancer and Haematology Service, Christchurch, New Zealand., Bartolomeo MD; Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Bridgewater J; University College London Cancer Institute, London, UK., Coveler AL; University of Washington, Seattle, Washington., Hidalgo M; Centro Integral Oncologico Clara Campal (CIOCC), Madrid, Spain., Kapp AV; Genentech, Inc., South San Francisco, California., Sufan RI; Genentech, Inc., South San Francisco, California., McCall BB; Genentech, Inc., South San Francisco, California., Hanley WD; Genentech, Inc., South San Francisco, California., Penuel EM; Genentech, Inc., South San Francisco, California., Pirzkall A; Genentech, Inc., South San Francisco, California., Tabernero J; Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, CIBERONC, Barcelona, Spain.
Source: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2018 May 15; Vol. 24 (10), pp. 2276-2284. Date of Electronic Publication: 2018 Mar 05.
Publication Type: Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 9502500 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 29506988
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Phase II Study of the Dual EGFR/HER3 Inhibitor Duligotuzumab (MEHD7945A) versus Cetuximab in Combination with FOLFIRI in Second-Line RAS Wild-Type Metastatic Colorectal Cancer.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Hill+AG%22">Hill AG</searchLink>; Tasman Oncology Research, Southport, Australia. andrewgrahamhill@gmail.com.<br /><searchLink fieldCode="AU" term="%22Findlay+MP%22">Findlay MP</searchLink>; Discipline of Oncology, University of Auckland, Auckland, New Zealand.<br /><searchLink fieldCode="AU" term="%22Burge+ME%22">Burge ME</searchLink>; Royal Brisbane and Women's Hospital, Herston, Australia; University of Queensland, Queensland, Australia.<br /><searchLink fieldCode="AU" term="%22Jackson+C%22">Jackson C</searchLink>; Department of Medicine, Dunedin School of Medicine, University of Otago, Dunedin, New Zealand.<br /><searchLink fieldCode="AU" term="%22Alfonso+PG%22">Alfonso PG</searchLink>; Gregorio Marañón Hospital, Madrid, Spain.<br /><searchLink fieldCode="AU" term="%22Samuel+L%22">Samuel L</searchLink>; Aberdeen Royal Infirmary, Aberdeen, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Ganju+V%22">Ganju V</searchLink>; Peninsula Oncology Centre, Frankston, Australia.<br /><searchLink fieldCode="AU" term="%22Karthaus+M%22">Karthaus M</searchLink>; Staedtisches Klinikum Muenchen GmbH-Klinikum Neuperlach, Munich, Germany.<br /><searchLink fieldCode="AU" term="%22Amatu+A%22">Amatu A</searchLink>; Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milan, Italy.<br /><searchLink fieldCode="AU" term="%22Jeffery+M%22">Jeffery M</searchLink>; Canterbury Regional Cancer and Haematology Service, Christchurch, New Zealand.<br /><searchLink fieldCode="AU" term="%22Bartolomeo+MD%22">Bartolomeo MD</searchLink>; Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.<br /><searchLink fieldCode="AU" term="%22Bridgewater+J%22">Bridgewater J</searchLink>; University College London Cancer Institute, London, UK.<br /><searchLink fieldCode="AU" term="%22Coveler+AL%22">Coveler AL</searchLink>; University of Washington, Seattle, Washington.<br /><searchLink fieldCode="AU" term="%22Hidalgo+M%22">Hidalgo M</searchLink>; Centro Integral Oncologico Clara Campal (CIOCC), Madrid, Spain.<br /><searchLink fieldCode="AU" term="%22Kapp+AV%22">Kapp AV</searchLink>; Genentech, Inc., South San Francisco, California.<br /><searchLink fieldCode="AU" term="%22Sufan+RI%22">Sufan RI</searchLink>; Genentech, Inc., South San Francisco, California.<br /><searchLink fieldCode="AU" term="%22McCall+BB%22">McCall BB</searchLink>; Genentech, Inc., South San Francisco, California.<br /><searchLink fieldCode="AU" term="%22Hanley+WD%22">Hanley WD</searchLink>; Genentech, Inc., South San Francisco, California.<br /><searchLink fieldCode="AU" term="%22Penuel+EM%22">Penuel EM</searchLink>; Genentech, Inc., South San Francisco, California.<br /><searchLink fieldCode="AU" term="%22Pirzkall+A%22">Pirzkall A</searchLink>; Genentech, Inc., South San Francisco, California.<br /><searchLink fieldCode="AU" term="%22Tabernero+J%22">Tabernero J</searchLink>; Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, CIBERONC, Barcelona, Spain.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%229502500%22">Clinical cancer research : an official journal of the American Association for Cancer Research</searchLink> [Clin Cancer Res] 2018 May 15; Vol. 24 (10), pp. 2276-2284. <i>Date of Electronic Publication: </i>2018 Mar 05.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22American+Association+for+Cancer+Research%22">American Association for Cancer Research </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>9502500 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1557-3265 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2210780432%22">10780432 </searchLink><i>NLM ISO Abbreviation: </i>Clin Cancer Res <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=29506988
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1158/1078-0432.CCR-17-0646
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 2276
    Titles:
      – TitleFull: Phase II Study of the Dual EGFR/HER3 Inhibitor Duligotuzumab (MEHD7945A) versus Cetuximab in Combination with FOLFIRI in Second-Line RAS Wild-Type Metastatic Colorectal Cancer.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Hill AG
      – PersonEntity:
          Name:
            NameFull: Findlay MP
      – PersonEntity:
          Name:
            NameFull: Burge ME
      – PersonEntity:
          Name:
            NameFull: Jackson C
      – PersonEntity:
          Name:
            NameFull: Alfonso PG
      – PersonEntity:
          Name:
            NameFull: Samuel L
      – PersonEntity:
          Name:
            NameFull: Ganju V
      – PersonEntity:
          Name:
            NameFull: Karthaus M
      – PersonEntity:
          Name:
            NameFull: Amatu A
      – PersonEntity:
          Name:
            NameFull: Jeffery M
      – PersonEntity:
          Name:
            NameFull: Bartolomeo MD
      – PersonEntity:
          Name:
            NameFull: Bridgewater J
      – PersonEntity:
          Name:
            NameFull: Coveler AL
      – PersonEntity:
          Name:
            NameFull: Hidalgo M
      – PersonEntity:
          Name:
            NameFull: Kapp AV
      – PersonEntity:
          Name:
            NameFull: Sufan RI
      – PersonEntity:
          Name:
            NameFull: McCall BB
      – PersonEntity:
          Name:
            NameFull: Hanley WD
      – PersonEntity:
          Name:
            NameFull: Penuel EM
      – PersonEntity:
          Name:
            NameFull: Pirzkall A
      – PersonEntity:
          Name:
            NameFull: Tabernero J
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 15
              M: 05
              Text: 2018 May 15
              Type: published
              Y: 2018
          Identifiers:
            – Type: issn-electronic
              Value: 1557-3265
          Numbering:
            – Type: volume
              Value: 24
            – Type: issue
              Value: 10
          Titles:
            – TitleFull: Clinical cancer research : an official journal of the American Association for Cancer Research
              Type: main
ResultId 1